lisavanbulin

01/01/2020 - "A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors."
12/01/2022 - "Mice bearing intracranial tumors received lisavanbulin +/-RT +/-TMZ and followed for survival. "
12/01/2022 - "The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts. "
02/25/2020 - "Oral treatment with BAL101553 for 100 days provoked a large EB1 expression level-dependent survival benefit, together with a decrease in tumor growth and brain invasion. "
11/01/2016 - "Patterns of invasion and quantification of tumor cells in brain demonstrated that GBM6-sh0 cells were more invasive than GBM6-shEB1 cells, and that the antiproliferative and anti-invasive effects of BAL101553 were more potent in mice bearing control tumors than in EB1-downregulated tumors. "

01/01/2021 - "Our results show that BAL101553 is a promising therapeutic agent for glioblastoma and could synergize with innate immune stimulation. "
12/01/2022 - "Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models."
12/01/2022 - "Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules."
11/01/2016 - "These results support the potential of BAL101553 for glioblastoma treatment, with EB1 expression as a predictive biomarker of response. "
11/01/2016 - "The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells."

01/01/2023 - "Three patients in the ovarian cancer cohort had stable disease with lesion size reductions after two cycles of treatment; in the glioblastoma cohort, one patient showed partial response with a > 90% glioblastoma area reduction as best response, and one patient had stable disease after eight cycles of treatment. Conclusion. This study demonstrated a favorable safety and tolerability profile of 48-hour continuous IV infusion of lisavanbulin in patients with solid extracranial tumors or glioblastoma. Clinicaltrials.gov registration: NCT02895360."
01/01/2023 - "Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study."

01/01/2023 - "These data show the basis for further preclinical and clinical evaluation of lisavanbulin in the lymphoma field."
01/01/2023 - "The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models."

01/01/2021 - "Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)."